1. Home
  2. HYFT vs SERA Comparison

HYFT vs SERA Comparison

Compare HYFT & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HYFT

MindWalk Holdings Corp.

N/A

Current Price

$1.31

Market Cap

69.6M

Sector

Health Care

ML Signal

N/A

Logo Sera Prognostics Inc.

SERA

Sera Prognostics Inc.

N/A

Current Price

$1.87

Market Cap

77.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HYFT
SERA
Founded
1983
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Precision Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
69.6M
77.2M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
HYFT
SERA
Price
$1.31
$1.87
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
312.6K
22.8K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
14.66
EPS
N/A
N/A
Revenue
N/A
$77,000.00
Revenue This Year
N/A
$25.84
Revenue Next Year
$51.71
$715.79
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.05
$1.37
52 Week High
$3.00
$4.34

Technical Indicators

Market Signals
Indicator
HYFT
SERA
Relative Strength Index (RSI) 46.21 20.26
Support Level N/A $1.37
Resistance Level $2.17 $2.00
Average True Range (ATR) 0.09 0.20
MACD 0.02 -0.03
Stochastic Oscillator 66.25 3.63

Price Performance

Historical Comparison
HYFT
SERA

About HYFT MindWalk Holdings Corp.

MindWalk Holdings Corp is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT technology and the LensAI platform, MindWalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed.

About SERA Sera Prognostics Inc.

Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.

Share on Social Networks: